Burden of eosinophilic esophagitis in adult and adolescent patients: results from a real-world analysis
Diseases of the Esophagus · 2025
DOI: 10.1093/dote/doaf024 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diseases of the Esophagus, 2025. Verfasst von Alain M Schoepfer und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 44, 1005 Lausanne, Sw…. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Quality of Life, Cost of Illness, Patient Acceptance of Health Care. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Real-world data on the impact of eosinophilic esophagitis (EoE) in patients are limited. This study assessed clinical characteristics, healthcare resource utilization (HCRU), symptoms, comorbidities, and quality of life (QoL) of EoE patients.
Methods
The multicountry cross-sectional survey, Adelphi EoE Disease Specific Programme™, collected physician and patient-reported data on clinical characteristics, HCRU, symptoms, comorbidities, and QOL of EoE patients with past/current proton pump inhibitor use and ongoing dysphagia-related symptoms (September to December 2020) at study entry.
Results
Physicians provided clinical characteristics, symptom, comorbidity, and HCRU data for 412 patients (12–17 years: 8%; ≥18 years: 92%); and 161 of these patients (12–17 years: 6%; ≥18 years: 94%) provided symptom and QOL data. Of the 412 patients, 67% were male, with a mean (SD) age of 37.0 (15.3) years. Overall, 74% of patients were currently being treated with corticosteroids (12–17 years: 88%; ≥18 years: 73%); 25% of patients had a history of esophageal dilations (12–17 years: 19%; ≥18 years: 26%); and 30% of patients had EoE-related emergency room visit (12–17 years: 31%; ≥18 years: 30%) in the last year. Among the 161 patients, heartburn (69%) was the most commonly reported symptom; the greatest negative impacts on QOL were reported for dysphagia-related anxiety, social activities involving food, and maintaining friendships (EoE Impact Questionnaire scores [1–5, low to high impact]: 1.6–2.2 for both age groups).
Conclusion
EoE patients continued to experience disease burden despite receiving treatment, highlighting the high unmet need for effective disease management in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 44, 1005 Lausanne, Switzerland.
- Adelphi Real World, Grimshaw Ln, Bollington, Macclesfield SK10 5JB, United Kingdom.
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd, Tarrytown, NY 10591, United States.
- Sanofi, 450 Water St, Cambridge, MA 02141, United States.
- Sanofi, 55 Corporate Dr, Bridgewater, NJ 08807, United States.
Zitieren
APA
Schoepfer, A. M., Olsen, S., Siddall, J., McCann, E., Kamat, S., Borsos, K., Khodzhayev, A., Radwan, A., Pela, T., Jacob-Nara, J., Tilton, S. T., & Thomas, R. B. (2025). Burden of eosinophilic esophagitis in adult and adolescent patients: results from a real-world analysis. Diseases of the Esophagus. https://doi.org/10.1093/dote/doaf024
Vancouver
Schoepfer AM, Olsen S, Siddall J, McCann E, Kamat S, Borsos K, et al. Burden of eosinophilic esophagitis in adult and adolescent patients: results from a real-world analysis. Diseases of the Esophagus. 2025. doi:10.1093/dote/doaf024
BibTeX
@article{Schoepfer2025,
author = {Schoepfer, Alain M and Olsen, Stevie and Siddall, James and McCann, Eilish and Kamat, Siddhesh and Borsos, Kinga and Khodzhayev, Angela and Radwan, Amr and Pela, Tiffany and Jacob-Nara, Juby and Tilton, Sarette T and Thomas, Ryan B},
title = {Burden of eosinophilic esophagitis in adult and adolescent patients: results from a real-world analysis},
journal = {Diseases of the Esophagus},
year = {2025},
doi = {10.1093/dote/doaf024}
}
EUVIMED